Bellot-Rojas Paula, Posadas-Sanchez Rosalinda, Caracas-Portilla Nacu, Zamora-Gonzalez Jose, Cardoso-Saldaña Guillermo, Jurado-Santacruz Fermin, Posadas-Romero Carlos
Centro Dermatologico Ladislao de la Pascua, Mexico City, Mexico.
J Drugs Dermatol. 2006 Oct;5(9):884-9.
Acanthosis nigricans (AN) is a skin condition commonly present on the neck of obese subjects. Obesity is often accompanied by insulin resistance and/or hyperinsulinemia. Metformin and rosiglitazone are 2 pharmacologic agents useful in conditions characterized by insulin resistance.
The aim of our study was to compare the efficacy of metformin versus rosiglitazone on AN lesions of the neck as well as their effects on metabolic and anthropometric variables.
This 12-week randomized, open-label pilot study involved overweight or obese subjects with AN treat with either metformin (n=4) or rosiglitazone (n=3).
Only the rosiglitazone group showed a significant reduction in insulin levels. No effect on the severity of AN was observed, but modest improvements of skin texture occurred in both treatment groups.
Metformin and rosiglitazone were well-tolerated. Although efficacy on skin lesions was very modest, their use in acanthotic subjects might be useful during longer treatment periods.
黑棘皮病（AN）是肥胖受试者颈部常见的一种皮肤疾病。肥胖常伴有胰岛素抵抗和/或高胰岛素血症。二甲双胍和罗格列酮是两种对以胰岛素抵抗为特征的病症有效的药物。
我们研究的目的是比较二甲双胍和罗格列酮对颈部AN皮损的疗效以及它们对代谢和人体测量学变量的影响。
这项为期12周的随机、开放标签的试点研究纳入了超重或肥胖的AN受试者，分别用二甲双胍（n = 4）或罗格列酮（n = 3）进行治疗。
只有罗格列酮组的胰岛素水平显著降低。未观察到对AN严重程度的影响，但两个治疗组的皮肤质地均有适度改善。
二甲双胍和罗格列酮耐受性良好。尽管对皮肤病变的疗效非常有限，但在较长治疗期间，它们在患黑棘皮病的受试者中的使用可能是有益的。
